Founded in 2014, Leucine Rich Bio operates in Health Tech industry. Initially focused on providing genomic diagnostics services, the company has since expanded its offerings to include microbiome test...
Funding stage:
Seed
Last funding:
24/10/2023
Total funding:
$338.45K+
Revenue:
Investors
Employee count:
40
Last 90d
40
Last 90d
Web traffic:
6.79K
6.79K
Last 30d
Last 30d
Glassdoor Rating:
Leucine Rich Bio: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders13
Latest Filing Date14 Nov 2024- Funding Events21
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Leucine Rich Bio
As of 15 November 2024, Leucine Rich Bio's equity is held by 12 shareholders, with the top three being Kumar Sankaran, Prabhath Manjappa Kamath, and Omphalos Ventures India LLP.
Kumar Sankaran holds the largest stake in Leucine Rich Bio at 26.2% as of 15 November 2024.
As of 15 November 2024, founders collectively hold 65.5% equity in Leucine Rich Bio.
As of 15 November 2024, investors collectively hold 27.0% equity in Leucine Rich Bio.
Leucine Rich Bio's ESOP pool stands at 7.4% of total equity as of 15 November 2024.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links